Zacks: Brokerages Anticipate BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to Post -$0.31 Earnings Per Share

Wall Street analysts forecast that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will announce earnings of ($0.31) per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for BioCryst Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.34) and the highest estimate coming in at ($0.25). BioCryst Pharmaceuticals reported earnings of ($0.19) per share in the same quarter last year, which would suggest a negative year over year growth rate of 63.2%. The business is expected to issue its next earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full-year earnings of ($1.21) per share for the current year, with EPS estimates ranging from ($1.27) to ($1.14). For the next financial year, analysts anticipate that the firm will post earnings of ($0.99) per share, with EPS estimates ranging from ($1.35) to ($0.69). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.28) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.28). BioCryst Pharmaceuticals had a negative net margin of 472.12% and a negative return on equity of 223.34%. The business had revenue of $5.89 million for the quarter, compared to analysts’ expectations of $2.92 million.

BCRX has been the subject of several research reports. Jefferies Financial Group dropped their target price on BioCryst Pharmaceuticals from $13.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, May 22nd. HC Wainwright initiated coverage on in a research note on Wednesday, May 22nd. They set a “buy” rating for the company. Piper Jaffray Companies set a $15.00 target price on BioCryst Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, April 22nd. Barclays set a €16.80 ($19.53) target price on Deutsche Telekom and gave the stock a “neutral” rating in a research note on Tuesday, April 2nd. Finally, Royal Bank of Canada restated a “buy” rating on shares of PrairieSky Royalty in a research note on Friday, May 24th. Six research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. BioCryst Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $9.56.

BioCryst Pharmaceuticals stock traded up $0.02 during mid-day trading on Friday, hitting $3.60. The company had a trading volume of 760,900 shares, compared to its average volume of 1,508,226. The company has a debt-to-equity ratio of 2.38, a current ratio of 1.77 and a quick ratio of 1.76. BioCryst Pharmaceuticals has a 12-month low of $2.80 and a 12-month high of $9.95. The firm’s fifty day moving average is $3.54. The stock has a market cap of $396.01 million, a P/E ratio of -3.67 and a beta of 2.05.

In other BioCryst Pharmaceuticals news, CFO Thomas R. Staab II sold 7,750 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $7.30, for a total value of $56,575.00. Following the completion of the sale, the chief financial officer now owns 140,426 shares in the company, valued at $1,025,109.80. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Thomas R. Staab II sold 19,500 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $7.70, for a total value of $150,150.00. Following the completion of the sale, the insider now owns 142,426 shares of the company’s stock, valued at approximately $1,096,680.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 67,500 shares of company stock valued at $517,223. 5.20% of the stock is owned by company insiders.

Several large investors have recently added to or reduced their stakes in BCRX. Paloma Partners Management Co acquired a new position in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $84,000. Amalgamated Bank acquired a new position in shares of BioCryst Pharmaceuticals in the fourth quarter valued at approximately $122,000. Summit Securities Group LLC acquired a new position in shares of BioCryst Pharmaceuticals in the first quarter valued at approximately $132,000. Legal & General Group Plc increased its holdings in shares of BioCryst Pharmaceuticals by 14.5% in the fourth quarter. Legal & General Group Plc now owns 19,315 shares of the biotechnology company’s stock valued at $156,000 after purchasing an additional 2,453 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of BioCryst Pharmaceuticals in the first quarter valued at approximately $169,000. 91.98% of the stock is currently owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Further Reading: What are different types of coverage ratios?

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.